These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 35007722)

  • 1. Effect of removal of the 14-hydroxy group on the affinity of the 4,5-epoxymorphinan derivatives for orexin and opioid receptors.
    Katoh K; Yamamoto N; Ishikawa Y; Irukayama-Tomobe Y; Tanimura R; Saitoh T; Nagumo Y; Kutsumura N; Yanagisawa M; Nagase H
    Bioorg Med Chem Lett; 2022 Mar; 59():128527. PubMed ID: 35007722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Essential structure of orexin 1 receptor antagonist YNT-707: Conversion of the 16-cyclopropylmethyl group to the 16-sulfonamide group in d-nor-nalfurafine derivatives.
    Katoh K; Kutsumura N; Yamamoto N; Nagumo Y; Saitoh T; Ishikawa Y; Irukayama-Tomobe Y; Tanimura R; Yanagisawa M; Nagase H
    Bioorg Med Chem Lett; 2022 Mar; 59():128550. PubMed ID: 35041942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of attenuation effect of orexin 1 receptor to aversion of nalfurafine: Synthesis and evaluation of D-nor-nalfurafine derivatives and analyses of the three active conformations of nalfurafine.
    Nagumo Y; Katoh K; Iio K; Saitoh T; Kutsumura N; Yamamoto N; Ishikawa Y; Irukayama-Tomobe Y; Ogawa Y; Baba T; Tanimura R; Yanagisawa M; Nagase H
    Bioorg Med Chem Lett; 2020 Sep; 30(17):127360. PubMed ID: 32738987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Essential structure of orexin 1 receptor antagonist YNT-707, Part I: Role of the 4,5-epoxy ring for binding with orexin 1 receptor.
    Yamamoto N; Ohrui S; Okada T; Yata M; Saitoh T; Kutsumura N; Nagumo Y; Irukayama-Tomobe Y; Ogawa Y; Ishikawa Y; Watanabe Y; Hayakawa D; Gouda H; Yanagisawa M; Nagase H
    Bioorg Med Chem Lett; 2017 Sep; 27(17):4176-4179. PubMed ID: 28739044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Essential structure of orexin 1 receptor antagonist YNT-707, Part IV: The role of D-ring in 4,5-epoxymorphinan on the orexin 1 receptor antagonistic activity.
    Saitoh T; Seki K; Nakajima R; Yamamoto N; Kutsumura N; Nagumo Y; Irukayama-Tomobe Y; Ogawa Y; Ishikawa Y; Tanimura R; Yanagisawa M; Nagase H
    Bioorg Med Chem Lett; 2019 Sep; 29(18):2655-2658. PubMed ID: 31375290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Essential structure of orexin 1 receptor antagonist YNT-707, Part II: Drastic effect of the 14-hydroxy group on the orexin 1 receptor antagonistic activity.
    Ohrui S; Yamamoto N; Saitoh T; Kutsumura N; Nagumo Y; Irukayama-Tomobe Y; Ogawa Y; Ishikawa Y; Watanabe Y; Hayakawa D; Gouda H; Yanagisawa M; Nagase H
    Bioorg Med Chem Lett; 2018 Feb; 28(4):774-777. PubMed ID: 29338909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Essential structure of orexin 1 receptor antagonist YNT-707, part III: Role of the 14-hydroxy and the 3-methoxy groups in antagonistic activity toward the orexin 1 receptor in YNT-707 derivatives lacking the 4,5-epoxy ring.
    Yamamoto N; Ohrui S; Okada T; Saitoh T; Kutsumura N; Nagumo Y; Irukayama-Tomobe Y; Ogawa Y; Ishikawa Y; Watanabe Y; Hayakawa D; Gouda H; Yanagisawa M; Nagase H
    Bioorg Med Chem; 2019 Apr; 27(8):1747-1758. PubMed ID: 30871861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Morphinan derivatives with an oxabicyclo[3.2.1]octane structure as dual agonists toward δ and κ opioid receptors.
    Uenohara Y; Tsumura S; Hirayama S; Higashi E; Watanabe Y; Gouda H; Nagase H; Fujii H
    Bioorg Med Chem; 2022 Jan; 53():116552. PubMed ID: 34894610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and Synthesis of Potent and Highly Selective Orexin 1 Receptor Antagonists with a Morphinan Skeleton and Their Pharmacologies.
    Nagase H; Yamamoto N; Yata M; Ohrui S; Okada T; Saitoh T; Kutsumura N; Nagumo Y; Irukayama-Tomobe Y; Ishikawa Y; Ogawa Y; Hirayama S; Kuroda D; Watanabe Y; Gouda H; Yanagisawa M
    J Med Chem; 2017 Feb; 60(3):1018-1040. PubMed ID: 28051300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Essential structure of orexin 1 receptor antagonist YNT-707, part V: Structure-activity relationship study of the substituents on the 17-amino group.
    Saitoh T; Seki K; Nakajima R; Yamamoto N; Kutsumura N; Nagumo Y; Irukayama-Tomobe Y; Ogawa Y; Ishikawa Y; Yanagisawa M; Nagase H
    Bioorg Med Chem Lett; 2020 Feb; 30(3):126893. PubMed ID: 31879208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis of new opioid derivatives with a propellane skeleton and their pharmacologies: Part 5, novel pentacyclic propellane derivatives with a 6-amide side chain.
    Nakajima R; Yamamoto N; Hirayama S; Iwai T; Saitoh A; Nagumo Y; Fujii H; Nagase H
    Bioorg Med Chem; 2015 Oct; 23(19):6271-9. PubMed ID: 26346669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor.
    Schattauer SS; Kuhar JR; Song A; Chavkin C
    Cell Signal; 2017 Apr; 32():59-65. PubMed ID: 28088389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Essential structure of opioid κ receptor agonist nalfurafine for binding to the κ receptor 2: synthesis of decahydro(iminoethano)phenanthrene derivatives and their pharmacologies.
    Nagase H; Imaide S; Hirayama S; Nemoto T; Fujii H
    Bioorg Med Chem Lett; 2012 Aug; 22(15):5071-4. PubMed ID: 22742909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Essential structure of the κ opioid receptor agonist nalfurafine for binding to the κ receptor.
    Nagase H; Fujii H
    Curr Pharm Des; 2013; 19(42):7400-14. PubMed ID: 23448474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Essential structure of opioid κ receptor agonist nalfurafine for binding to the κ receptor 3: synthesis of decahydro(iminoethano)phenanthrene derivatives with an oxygen functionality at the 3-position and their pharmacologies.
    Fujii H; Imaide S; Hirayama S; Nemoto T; Gouda H; Hirono S; Nagase H
    Bioorg Med Chem Lett; 2012 Dec; 22(24):7711-4. PubMed ID: 23103094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Verifying the role of 3-hydroxy of 17-cyclopropylmethyl-4,5α-epoxy-3,14β-dihydroxy-6β-[(4'-pyridyl) carboxamido]morphinan derivatives via their binding affinity and selectivity profiles on opioid receptors.
    Huang B; Gunta R; Wang H; Li M; Cao D; Mendez RE; Gillespie JC; Chen C; Huang LM; Liu-Chen LY; Selley DE; Zhang Y
    Bioorg Chem; 2021 Apr; 109():104702. PubMed ID: 33631465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Syntheses of 4,6'-epoxymorphinan derivatives and their pharmacologies.
    Nemoto T; Fujii H; Narita M; Miyoshi K; Nakamura A; Suzuki T; Nagase H
    Bioorg Med Chem; 2008 Apr; 16(8):4304-12. PubMed ID: 18337104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of 17-N substituents on the activity of the opioid κ receptor in nalfurafine derivatives.
    Nemoto T; Yamamoto N; Wada N; Harada Y; Tomatsu M; Ishihara M; Hirayama S; Iwai T; Fujii H; Nagase H
    Bioorg Med Chem Lett; 2013 Jan; 23(1):268-72. PubMed ID: 23200250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Essential structure of opioid κ receptor agonist nalfurafine for binding to κ receptor 1: synthesis of decahydroisoquinoline derivatives and their pharmacologies.
    Nagase H; Imaide S; Yamada T; Hirayama S; Nemoto T; Yamaotsu N; Hirono S; Fujii H
    Chem Pharm Bull (Tokyo); 2012; 60(8):945-8. PubMed ID: 22863695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of cocaine-related behaviors by low doses of the potent KOR agonist nalfurafine in male C57BL6 mice.
    Dunn A; Windisch K; Ben-Ezra A; Pikus P; Morochnik M; Erazo J; Reed B; Kreek MJ
    Psychopharmacology (Berl); 2020 Aug; 237(8):2405-2418. PubMed ID: 32435819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.